ArticleScientific reports2017
AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 29 citations in OpenAlex.
- Translational PBPK Modeling and Exposure-Response Analysis of AT-RvD1 for Treating Sjögren's Disease.Clinical and translational science · 2026Article
- Activation of Human FPR2 with AT-RvD1 Resolves Acute Sialadenitis in Vivo.Inflammation · 2025Article
- Lipid Metabolism: An Emerging Player in Sjögren's Syndrome.Clinical reviews in allergy & immunology · 2025Review
- Salivary gland macrophages in health and disease: heterogeneity, niche crosstalk, and therapeutic avenues.Frontiers in immunology · 2025Review
- A potent proresolving mediator 17R-resolvin D2 from human macrophages, monocytes, and saliva.Science advances · 2024Article
- ALX/FPR2 Activation by Stereoisomers of D1 Resolvins Elucidating with Molecular Dynamics Simulation.The journal of physical chemistry. B · 2023Article
- Co-Administration of Resolvin D1 and Peripheral Nerve-Derived Stem Cell Spheroids as a Therapeutic Strategy in a Rat Model of Spinal Cord Injury.International journal of molecular sciences · 2023Article
- A combination treatment of low-dose dexamethasone and aspirin-triggered resolvin D1 reduces Sjögren syndrome-like features in a mouse model.JADA foundational science · 2023Article
- Specialized pro-resolving receptors are expressed in salivary glands with Sjögren's syndrome.Annals of diagnostic pathology · 2022Article
- Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome.Frontiers in immunology · 2022Review
- Ruscogenin Ameliorated Sjögren's Syndrome by Inhibiting NLRP3 Inflammasome Activation.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Qing Zao Fang (QZF) Alleviates the Inflammatory Microenvironment of the Submandibular Gland in Sjögren's Syndrome Based on the PI3K/Akt/HIF-1Disease markers · 2022Article
- Sex Differences in Otolaryngology: Focus on the Emerging Role of Estrogens in Inflammatory and Pro-Resolving Responses.International journal of molecular sciences · 2021Review
- SPM Receptor Expression and Localization in Irradiated Salivary Glands.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Article
- Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling.Clinical and translational science · 2021Article
- The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke.International journal of molecular sciences · 2020Review
- Formyl peptide receptors in the mucosal immune system.Experimental & molecular medicine · 2020Review
- Sex-mediated elevation of the specialized pro-resolving lipid mediator levels in a Sjögren's syndrome mouse model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome.Clinical and experimental dental research · 2020Article
- Agonist-induced 4-1BB activation prevents the development of Sjӧgren's syndrome-like sialadenitis in non-obese diabetic mice.Biochimica et biophysica acta. Molecular basis of disease · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Sjögren's syndrome (SS) is a chronic inflammatory autoimmune disease characterized by diminished secretory function of the exocrine glands. Treatments for hyposalivation are limited to the use of saliva substitutes and medications that provide only temporary relief. In light of the high degree of need and the limitations of current therapies, development of alternative treatments to restore functioning is essential. Resolvins (Rv), which are highly potent lipid mediators, offer a viable alternative for better treating inflammatory diseases such as SS. The goal of this study was to determine whether systemic preventive treatment with Aspirin-triggered RvD1 (AT-RvD1) reduces inflammation and preserves secretory functioning in NOD/ShiLtJ SS-like mice. Our results indicate that systemic treatment with AT-RvD1 diminishes the progression of the disease in salivary epithelium from female mice as follows: (a) improves secretory function, (b) reduces pro-inflammatory molecule gene expression, (c) increases anti-inflammatory molecule gene expression and (d) induces M2 macrophage polarization. Finally, AT-RvD1 decreases lymphocytic infiltration into the salivary glands when used with small doses of the steroid, dexamethasone, and promotes the tissue healing process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.